govt.fyi
Back to SB 2074
Oklahoma Legislature· SB 2074Vetoed 04/22/2026

An act relating to pharmacy benefits managers, the official text

Shown verbatim: the complete text as captured from the official PDF posted by the Oklahoma Legislature, fetched 2026-07-23. Page and line markers are part of the official record; nothing is edited or removed. The official bill page.
1                   STATE OF OKLAHOMA

1

2                  2nd Session of the 60th Legislature (2026)

2

3 SENATE BILL 2074              By: Alvord
3

4

4

5

5

6                   AS INTRODUCED

6

7   An Act relating to pharmacy benefits managers;

7   amending 59 O.S. 2021, Sections 357, as last amended

8   by Section 2, Chapter 414, O.S.L. 2025, and 360, as

8   last amended by Section 8, Chapter 300, O.S.L. 2025

9   (59 O.S. Supp. 2025, Sections 357 and 360), which

9   relate to definitions and pharmacy benefits manager

10  contractual duties to provider; defining term;

10  prohibiting certain pharmacy benefits manager from

11  refusing to accept certain documentation; requiring

11  certain adjusted reimbursement amount if certain

12  appeal is approved; allowing certain provider to

12  request certain reversal or rebilling; requiring

13  certain information to be included in certain appeal;

13  requiring certain adjustments to include certain

14  claim-level details within certain time period;

14  prohibiting certain reimbursement amounts; updating

15  statutory references; updating statutory language;

15  and providing an effective date.

16

16

17

17

18 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
18

19  SECTION 1.      AMENDATORY  59 O.S. 2021, Section 357, as last

19

20 amended by Section 2, Chapter 414, O.S.L. 2025 (59 O.S. Supp. 2025,
20

21 Section 357), is amended to read as follows:
21

22  Section 357. A. As used in Sections 357 through 360 360.1 of

22

23 this title:
23

24

24

    Req. No. 2584                                              Page 1
1   1. "Acquisition cost" means the total amount paid by a provider

1

2 to acquire a drug, medical product, or device at the time of
2

3 purchase as evidenced by verifiable purchase documentation such as
3

4 an invoice or electronic price file. Acquisition cost shall include
4

5 purchase price, procurement fees, and associated shipping or
5

6 handling charges and shall not include any post-purchase rebates,
6

7 discounts, or credits that are not guaranteed and applied at the
7

8 time of sale;
8

9   2. "Covered entity" means a nonprofit hospital or medical

9

10 service organization, for-profit hospital or medical service
10

11 organization, insurer, health benefit plan, health maintenance
11

12 organization, health program administered by the state in the
12

13 capacity of providing health coverage, or an employer, labor union,
13

14 or other group of persons that provides health coverage to persons
14

15 in this state. This term does not include a health benefit plan
15

16 that provides coverage only for accidental injury, specified
16

17 disease, hospital indemnity, disability income, or other limited
17

18 benefit health insurance policies and contracts that do not include
18

19 prescription drug coverage;
19

20  2. 3. "Covered individual" means a member, participant,

20

21 enrollee, contract holder or policy holder or beneficiary of a
21

22 covered entity who is provided health coverage by the covered
22

23 entity. A covered individual includes any dependent or other person
23

24

24

    Req. No. 2584               Page 2
1 provided health coverage through a policy, contract or plan for a
1

2 covered individual;
2

3   3. 4. "Department" means the Insurance Department;

3

4   4. 5. "Effective rate contracting" means any agreement or

4

5 arrangement between a pharmacy or contracting agent acting on behalf
5

6 of a pharmacy and a pharmacy benefits manager for pharmaceuticals
6

7 based on the effective rate of payment rather than a predetermined
7

8 fixed price or fixed discount percentage;
8

9   5. 6. "Maximum allowable cost", "MAC", or "MAC list" means the

9

10 list of drug products delineating the maximum per-unit reimbursement
10

11 for multiple-source prescription drugs, medical product products, or
11

12 device devices;
12

13  6. 7. "Multisource drug product reimbursement" (reimbursement)

13

14 means the total amount paid to a pharmacy inclusive of any reduction
14

15 in payment to the pharmacy, excluding prescription dispense fees and
15

16 professional fees;
16

17  7. 8. "Office" means the Office of the Attorney General;

17

18  8. 9. "Pharmacy benefits management" means a service provided

18

19 to covered entities to facilitate the provision of prescription drug
19

20 benefits to covered individuals within the state, including
20

21 negotiating pricing and other terms with drug manufacturers and
21

22 providers. Pharmacy benefits management may include any or all of
22

23 the following services:
23

24

24

    Req. No. 2584                                               Page 3
1   a. claims processing, retail network management and

1

2                  payment of claims to pharmacies for prescription drugs

2

3                  dispensed to covered individuals,

3

4   b. clinical formulary development and management

4

5                  services, or

5

6   c. rebate contracting and administration;

6

7   9. 10. "Pharmacy benefits manager" or "PBM" means a person,

7

8 business, or other entity that performs pharmacy benefits
8

9 management. The term shall include a person or entity acting on
9

10 behalf of a PBM in a contractual or employment relationship in the
10

11 performance of pharmacy benefits management for a managed care
11

12 company, nonprofit hospital, medical service organization, insurance
12

13 company, third-party payor, or a health program administered by an
13

14 agency or department of this state;
14

15  10. 11. "Plan sponsor" means the employers, insurance

15

16 companies, unions and health maintenance organizations or any other
16

17 entity responsible for establishing, maintaining, or administering a
17

18 health benefit plan on behalf of covered individuals; and
18

19  11. 12. "Provider" means a pharmacy licensed by the State Board

19

20 of Pharmacy, or an agent or representative of a pharmacy, including,
20

21 but not limited to, the pharmacy's contracting agent, which
21

22 dispenses prescription drugs or devices to covered individuals.
22

23  B. Nothing in the definition of pharmacy benefits management or

23

24 pharmacy benefits manager in the Patient's Right to Pharmacy Choice
24

    Req. No. 2584                                               Page 4
1 Act, Pharmacy Audit Integrity Act, or Sections 357 through 360 360.1
1

2 of this title shall deem an employer a "pharmacy benefits manager"
2

3 of its own self-funded health benefit plan, except, to the extent
3

4 permitted by applicable law, where the employer, without the
4

5 utilization of a third party and unrelated to the employer's own
5

6 pharmacy:
6

7      a. negotiates 1. Negotiates directly with drug

7

8 manufacturers,;
8

9      b. processes 2. Processes claims on behalf of its members,;

9

10 or
10

11     c. manages 3. Manages its own retail network of pharmacies.

11

12     SECTION 2.  AMENDATORY  59 O.S. 2021, Section 360, as last

12

13 amended by Section 8, Chapter 300, O.S.L. 2025 (59 O.S. Supp. 2025,
13

14 Section 360), is amended to read as follows:
14

15     Section 360. A. The pharmacy benefits manager (PBM) shall,

15

16 with respect to contracts between a pharmacy benefits manager and a
16

17 provider, including a pharmacy service administrative organization:
17

18     l. Include in such contracts the specific sources utilized to

18

19 determine the maximum allowable cost (MAC) pricing of the pharmacy,
19

20 update MAC pricing at least every seven (7) calendar days, and
20

21 establish a process for providers to readily access the MAC list
21

22 specific to that provider;
22

23     2. In order to place a drug on the MAC list, ensure that the

23

24 drug is listed as "A" or "B" rated in the most recent version of the
24

    Req. No. 2584                                      Page 5
1 United States Food and Drug Administration (FDA) Approved Drug
1

2 Products with Therapeutic Equivalence Evaluations, also known as the
2

3 Orange Book, and the drug is generally available for purchase by
3

4 pharmacies in the state from national or regional wholesalers and is
4

5 not obsolete;
5

6  3. Ensure dispensing fees are not included in the calculation

6

7 of MAC price reimbursement to pharmacy providers;
7

8  4. Provide a reasonable administration appeals procedure to

8

9 allow a provider, a provider's representative and a pharmacy service
9

10 administrative organization to contest reimbursement amounts within
10

11 fourteen (14) calendar days of the final adjusted payment date. The
11

12 pharmacy benefits manager shall not prevent the pharmacy or the
12

13 pharmacy service administrative organization from filing
13

14 reimbursement appeals in an electronic batch format. The pharmacy
14

15 benefits manager must PBM shall respond to a provider, a provider's
15

16 representative and a pharmacy service administrative organization
16

17 who have contested a reimbursement amount through this procedure
17

18 within ten (10) calendar days. The pharmacy benefits manager must
18

19 PBM shall respond in an electronic batch format to reimbursement
19

20 appeals filed in an electronic batch format. The pharmacy benefits
20

21 manager PBM shall not require a pharmacy or pharmacy services
21

22 administrative organization to log into a system to upload
22

23 individual claim appeals or to download individual appeal responses.
23

24 A PBM shall not refuse to accept additional documentation from
24

   Req. No. 2584                                               Page 6
1 providers after the appeal submission. If a price update is
1

2 warranted, the pharmacy benefits manager PBM shall make the change
2

3 in the reimbursement amount, permit the dispensing pharmacy to
3

4 reverse and rebill the claim in question, and make the reimbursement
4

5 amount change retroactive and effective for all contracted
5

6 providers;
6

7   5. If a below-cost reimbursement appeal is denied, the PBM

7

8 shall provide the reason for the denial, including the National Drug
8

9 Code (NDC) number from, and the name of, the specific national or
9

10 regional wholesalers doing business in this state where the drug is
10

11 currently in stock and available for purchase by the dispensing
11

12 pharmacy at a price below the PBM's reimbursement price. The PBM
12

13 shall include documented proof from the specific national or
13

14 regional wholesalers doing business in this state showing that the
14

15 drug is currently in stock and available for purchase by the
15

16 dispensing pharmacy at a price below the PBM's reimbursement price.;
16

17  6. If the NDC number provided by the pharmacy benefits manager

17

18 PBM is not available below the acquisition cost obtained from the
18

19 pharmaceutical wholesaler from whom the dispensing pharmacy
19

20 purchases the majority of the prescription drugs that are dispensed,
20

21 the pharmacy benefits manager PBM shall immediately adjust the
21

22 reimbursement amount, permit the dispensing pharmacy to reverse and
22

23 rebill the claim in question, and make the reimbursement amount
23

24 adjustment retroactive and effective for all contracted providers;
24

    Req. No. 2584                                             Page 7
1 effective for all prescriptions of the appealed drug, medical
1

2 product, or device for patients covered under the same Bank
2

3 Identification Number (BIN) and Processor Control Number (PCN),
3

4 retroactive to the initially appealed claim's date of service. A
4

5 PBM shall notify the provider that an increase has been granted
5

6 because of a reimbursement appeal. If a claim subject to an
6

7 approved appeal is not reversed and reprocessed within thirty (30)
7

8 calendar days after the final appeal determination, the PBM shall
8

9 remit to the provider the full reimbursement amount required by the
9

10 approved appeal, including any retroactive adjustments and shall not
10

11 require the provider to refund or otherwise return any portion of
11

12 the reimbursement paid for that claim;
12

13  6. 7. Any appeal that results in an increase in the

13

14 reimbursement from the PBM that continues to be below the pharmacy's
14

15 acquisition cost shall be considered a denial under this section.
15

16 Any denial of an appeal shall follow the requirements of paragraph
16

17 paragraphs 5 and 6 of this subsection; and
17

18  7. 8. The PBM shall not require a pharmacy to collect

18

19 additional monies following a successful below-cost reimbursement
19

20 appeal from any person or entity other than the PBM who adjudicated
20

21 the drug claim, including the patient or plan sponsor; and
21

22  9. Any adjustment to provider reimbursement shall be

22

23 accompanied by complete claim-level detail sufficient to reconcile
23

24 the adjustment, including identification of the original claim
24

    Req. No. 2584                                              Page 8
1 payment values and the revised values for all affected fields. An
1

2 adjustment for which such claim-level detail is not provided
2

3 contemporaneously shall be deemed incomplete.
3

4   B. The reimbursement appeal requirements in this section shall

4

5 apply to all drugs, medical products, or devices reimbursed
5

6 according to any payment methodology, including, but not limited to:
6

7   1. Average acquisition cost, including the National Average

7

8 Drug Acquisition Cost;
8

9   2. Average manufacturer price;

9

10  3. Average wholesale price;

10

11  4. Brand effective rate or generic effective rate;

11

12  5. Discount indexing;

12

13  6. Federal upper limits;

13

14  7. Wholesale acquisition cost; and

14

15  8. Any other term that a pharmacy benefits manager PBM or an

15

16 insurer of a health benefit plan may use to establish reimbursement
16

17 rates to a pharmacist or pharmacy for pharmacist services.
17

18  C. The pharmacy benefits manager PBM shall not place a drug on

18

19 a MAC list, unless there are at least two therapeutically
19

20 equivalent, multiple-source drugs, generally available for purchase
20

21 by dispensing retail pharmacies from national or regional
21

22 wholesalers.
22

23  D. In the event that a drug is placed on the FDA Drug Shortages

23

24 Database, pharmacy benefits managers PBMs shall reimburse claims to
24

    Req. No. 2584                                              Page 9
1 pharmacies at no less than the wholesale acquisition cost for the
1

2 specific NDC number being dispensed.
2

3   E. The pharmacy benefits manager PBM shall not require

3

4 accreditation or licensing of providers, or any entity licensed or
4

5 regulated by the State Board of Pharmacy, other than by the State
5

6 Board of Pharmacy or federal government entity as a condition for
6

7 participation as a network provider.
7

8   F. A pharmacy or pharmacist may decline to provide the

8

9 pharmacist clinical or dispensing services to a patient or pharmacy
9

10 benefits manager if the pharmacy or pharmacist is to be paid less
10

11 than the pharmacy's cost for providing the pharmacist clinical or
11

12 dispensing services.
12

13  G. The pharmacy benefits manager PBM shall provide a dedicated

13

14 telephone number, email address and names of the personnel with
14

15 decision-making authority regarding MAC appeals and pricing.
15

16  H. A PBM shall not reimburse a provider for a prescription drug

16

17 or pharmacy service in an amount less than the national average drug
17

18 acquisition cost for the prescription drug or pharmacy service at
18

19 the time the drug is administered or dispensed, plus a professional
19

20 dispensing fee of no less than the Medicaid fee-for-service
20

21 professional dispensing fee rate established under rules promulgated
21

22 by the Oklahoma Health Care Authority Board. If the national
22

23 average drug acquisition cost is not available at the time a drug is
23

24 administered or dispensed, a PBM shall not reimburse in an amount
24

    Req. No. 2584                       Page 10
1 that is less than the wholesale acquisition cost of the drug
1

2 pursuant to 42 U.S.C., Section 1395w-3a(c)(6)(B), and shall
2

3 reimburse a professional dispensing fee of no less than the rate
3

4 established by the Board.
4

5   SECTION 3. This act shall become effective November 1, 2026.

5

6

6

7   60-2-2584      CAD       1/15/2026 11:52:08 AM

7

8

8

9

9

10

10

11

11

12

12

13

13

14

14

15

15

16

16

17

17

18

18

19

19

20

20

21

21

22

22

23

23

24

24

    Req. No. 2584                                   Page 11
Every fact on this page links to its source, starting with the official bill record.